Kither Biotech’s Post

Very happy to present our SIRIUS study (Solving Riddles Through Sequencing, clinicaltrials.gov: NCT05046444) at #AGD2024. In our head-to-head comparison with gold-standard diagnostics, WGTS enriched the diagnostic landscape for 26% of patients (29 out of 110) within 3 weeks, uncovering predominantly rare SNVs not analyzed in standard panels, CNVs too small to be detected by CBA, and aberrant expression patterns not assessed in conventional diagnostics. The anticipated improvements in turnaround times and cost-efficiency strongly suggest for WGTS's future integration into routine diagnostics. #LeukemiaDiagnostics #CancerGenomics https://www.genomnet.de/ MLL Münchner Leukämielabor

🌟 NEW EPISODE ALERT 🌟 Dive deep into the world of Idiopathic Pulmonary Fibrosis (IPF) with Dr. Victor Thannickal on our latest episode of BIO from the BAYOU. 🎙️ Learn about the symptoms, progression, and the groundbreaking drug therapies being developed to combat this devastating lung disease. 🔍 Highlights: • Understanding IPF fundamentals • Impact on patient lives • Innovative therapies from Dr. Thannickal’s lab • Latest research advancements 📲 Listen now and stay ahead in biotech developments! #Biotech #HealthcareInnovation #IPF #LungDisease #PharmaceuticalResearch ➡️ Listen to Episode 36 Now (link in comments)

Have you heard about this biotech developing muscle activators for heart diseases? ❤️ ⚒️ Cytokinetics is designing drugs that modulate the proteins involved in the bio-machinery of the cardiac muscle. This represents a major advancement for innovation in cardiac disease. 🫀 Labiotech has been in conversation with Robert Blum, CEO of Cytokinetics, about the company’s heart drug pipeline, including a phase 3 drug that has seen great results in treating a disease that causes sudden cardiac death in patients. 🏥 🎧 Tune into the latest episode of the Beyond Biotech Podcast to know more about Cytokinetics’ technology and progress! 👇  https://lnkd.in/dnh8X338 #BeyondBiotechPodcast #heartdisease #biotechinnovation #cardiachealth #medicaladvancements #drugpipeline American Heart Association

Congratulations to the entire team at Bitterroot Bio on the successful launch / dosing of first participants in a Phase I clinical trial for BRB-002! This pioneering study represents a significant step forward in the battle against atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality worldwide. 🔬 BRB-002 is not just another treatment; it's a novel protein therapy targeting CD47 with the potential to transform the cardiovascular health landscape. The dedication of the Bitterroot team to addressing unmet needs in cardio-immunology shines through this achievement. 💉 Dosing the first human participants marks a pivotal transition for Bitterroot into a clinical-stage company. This progress is a testament to the hard work and perseverance of the team, led by Craig Basson, MD, PhD, Chief Medical Officer. 👏 Here's to hoping that BRB-002 will bring new hope to patients and set new standards in cardiovascular care. Keep pushing the boundaries, Bitterroot Bio! #CardiovascularHealth #Innovation #ClinicalTrials #BitterrootBio #HealthcareInnovation #Biotech #Phase1 #ASCVD #Congratulations #lifescience

Join #SITC for the FREE Summit on Immunomodulation of ADCs on June 26. Discussion topics include the impact of ADCs on the immune system, clinical considerations surrounding ADCs, ADC combination therapies, and next generation immunoconjugates. Register: https://lnkd.in/gmgcVAd9

June has been Myasthenia Gravis (#MG) Awareness Month, a time dedicated to raising awareness of MG, a chronic neuromuscular autoimmune disease that affects a person’s ability to control their muscles, causing fatigue and muscle weakness. This #NeuromuscularDisease affects over 70,000 people in the United States alone, and 20 out of every 100,000 people worldwide. NMD Pharma is dedicated to developing treatments for MG, with an ongoing Phase 2b #ClinicalTrial of NMD670, our lead small molecule oral inhibitor of the skeletal muscle-specific CIC-1 ion channel that aims to enhance skeletal muscle activation and improve muscle function with potential to allow patients living with the disease to live better, more independent lives. We were happy to announce several weeks ago, in this MG Awareness Month, that our first patient was enrolled in this important study. It’s important to understand the challenges faced by those affected by MG and work together to continue to raise awareness and support those living with this disease, not only in June, but throughout the whole year. Please stay tuned throughout the year for more MG news and programs from NMD Pharma and others who are dedicated to help those affected by MG. #NMDPharma #MyastheniaGravis #MyastheniaGravisAwarenessMonth #Biotech #Innovation #RareDisease

Busy days at #EEC2024 in Bucharest! The European #Endometriosis Conference has been an excellent platform for engaging discussions with leading experts in the field, sharing valuable insights and learning from peers, and exploring potential collaborations. We were particularly excited to present our poster titled: "#Vipoglanstat, a non-hormonal treatment for endometriosis ready to start phase II." Vipoglanstat has demonstrated excellent pain-relieving effects in several preclinical inflammatory pain models, including an endometriosis disease model. Together with outstanding safety and tolerability at doses achieving full inhibition of its target enzyme, this paves the way for phase II development for endometriosis. #EuropeanEndometriosisLeague #womenshealth #nonhormonal

Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://bit.ly/3A80Q8t #LCSM

Today, on World Parkinson's Day, we, at iRegene Therapeutics, stand in solidarity with millions around the world affected by Parkinson's Disease. Our hearts and efforts go out to every individual and family touched by this condition. We understand the challenges and hardships faced by Parkinson's patients and their loved ones. It's a journey that requires strength, patience, and hope. In our pursuit to be a beacon of that hope, we are relentlessly focused and committed to accelerating the development of NouvNeu001, our pioneering treatment designed to make a significant difference. This groundbreaking therapy, focusing on dopaminergic neuron progenitors, is at the forefront of our efforts to offer new horizons to those affected by Parkinson's Disease. On this World Parkinson's Day, we reaffirm our pledge to not only accelerate the availability of NouvNeu001 but also to ensure that our journey is one of empathy, support, and unwavering dedication to all those awaiting a brighter future. Together, we believe we can make a difference. Together, we can change lives. #ParkinsonsDay #iRegeneTherapeutics #NouvNeu001 #HopeInScience #ChangeLives

Today, on World Parkinson's Day, we, at iRegene Therapeutics, stand in solidarity with millions around the world affected by Parkinson's Disease. Our hearts and efforts go out to every individual and family touched by this condition. We understand the challenges and hardships faced by Parkinson's patients and their loved ones. It's a journey that requires strength, patience, and hope. In our pursuit to be a beacon of that hope, we are relentlessly focused and committed to accelerating the development of NouvNeu001, our pioneering treatment designed to make a significant difference. This groundbreaking therapy, focusing on dopaminergic neuron progenitors, is at the forefront of our efforts to offer new horizons to those affected by Parkinson's Disease. On this World Parkinson's Day, we reaffirm our pledge to not only accelerate the availability of NouvNeu001 but also to ensure that our journey is one of empathy, support, and unwavering dedication to all those awaiting a brighter future. Together, we believe we can make a difference. Together, we can change lives. #ParkinsonsDay #iRegeneTherapeutics #NouvNeu001 #HopeInScience #ChangeLives